GlaxoSmithKline Pharmaceuticals Limited — Investor Meet, 29-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Pharmaceuticals Limited reported its Q2 FY25 financial highlights, achieving ₹1000 crore in revenue, a 5% growth, and a 15% increase in PAT to ₹249 crore. Key brands in General Medicines maintained market share, while the Pediatric Vaccines portfolio grew by 18%. The company declared a special interim dividend of ₹12 per share to celebrate 100 years in India. Digital initiatives continue to enhance customer engagement and operational efficiencies, reflected in improved EBITDA margins.